Skip to main content
Top
Published in: Trials 1/2016

Open Access 01-12-2016 | Methodology

A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization

Authors: Alexandra R. Brown, Byron J. Gajewski, Lauren S. Aaronson, Dinesh Pal Mudaranthakam, Suzanne L. Hunt, Scott M. Berry, Melanie Quintana, Mamatha Pasnoor, Mazen M. Dimachkie, Omar Jawdat, Laura Herbelin, Richard J. Barohn

Published in: Trials | Issue 1/2016

Login to get access

Abstract

Background

In the last few decades, the number of trials using Bayesian methods has grown rapidly. Publications prior to 1990 included only three clinical trials that used Bayesian methods, but that number quickly jumped to 19 in the 1990s and to 99 from 2000 to 2012. While this literature provides many examples of Bayesian Adaptive Designs (BAD), none of the papers that are available walks the reader through the detailed process of conducting a BAD. This paper fills that gap by describing the BAD process used for one comparative effectiveness trial (Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations) that can be generalized for use by others. A BAD was chosen with efficiency in mind. Response-adaptive randomization allows the potential for substantially smaller sample sizes, and can provide faster conclusions about which treatment or treatments are most effective. An Internet-based electronic data capture tool, which features a randomization module, facilitated data capture across study sites and an in-house computation software program was developed to implement the response-adaptive randomization.

Results

A process for adapting randomization with minimal interruption to study sites was developed. A new randomization table can be generated quickly and can be seamlessly integrated in the data capture tool with minimal interruption to study sites.

Conclusion

This manuscript is the first to detail the technical process used to evaluate a multisite comparative effectiveness trial using adaptive randomization. An important opportunity for the application of Bayesian trials is in comparative effectiveness trials. The specific case study presented in this paper can be used as a model for conducting future clinical trials using a combination of statistical software and a web-based application.

Trial registration

ClinicalTrials.gov Identifier: NCT02260388, registered on 6 October 2014
Literature
1.
go back to reference Bonangelino P, Irony T, Liang S, Li X, Mukhi V, Ruan S, Xu Y, Yang X, Wang C. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting. J Biopharm Stat. 2011;21(5):938–53.CrossRefPubMed Bonangelino P, Irony T, Liang S, Li X, Mukhi V, Ruan S, Xu Y, Yang X, Wang C. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting. J Biopharm Stat. 2011;21(5):938–53.CrossRefPubMed
2.
go back to reference Berry DA. A guide to drug discovery: Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27–36.CrossRefPubMed Berry DA. A guide to drug discovery: Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27–36.CrossRefPubMed
3.
go back to reference Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian adaptive methods for clinical trials. New York: CRC Press; 2011. Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian adaptive methods for clinical trials. New York: CRC Press; 2011.
6.
go back to reference Esserman LJ, Berry DA, Demichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30(26):3242–9.CrossRefPubMedPubMedCentral Esserman LJ, Berry DA, Demichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30(26):3242–9.CrossRefPubMedPubMedCentral
7.
go back to reference Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer—a step toward personalized medicine. Clinical Trials. 2008;5:181–93.CrossRefPubMed Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer—a step toward personalized medicine. Clinical Trials. 2008;5:181–93.CrossRefPubMed
8.
go back to reference Connor JT, Luce BR, Broglio KR, Ishak KJ, Mullins CD, Vanness DJ, Fleurence R, Saunders E, Davis BR. Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Clinical Trials. 2013;10(5):805–27.CrossRef Connor JT, Luce BR, Broglio KR, Ishak KJ, Mullins CD, Vanness DJ, Fleurence R, Saunders E, Davis BR. Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Clinical Trials. 2013;10(5):805–27.CrossRef
10.
go back to reference Pasnoor M, Nascimento OJ, Trivedi J, Wolfe GI, Nations S, Herbelin L, De Freitas MG, Quintanilha G, Khan S, Dimachkie M, Barohn R. North America and South America (NA-SA) neuropathy project. Int J Neurosci. 2013;123(8):563–7.CrossRefPubMed Pasnoor M, Nascimento OJ, Trivedi J, Wolfe GI, Nations S, Herbelin L, De Freitas MG, Quintanilha G, Khan S, Dimachkie M, Barohn R. North America and South America (NA-SA) neuropathy project. Int J Neurosci. 2013;123(8):563–7.CrossRefPubMed
11.
go back to reference Burckhardt CS, Jones KD. Adult measures of pain: The McGill Pain Questionnaire (MPQ), Rheumatoid Arthritis Pain Scale (RAPS), Short-Form McGill Pain Questionnaire (SF-MPQ), Verbal Descriptive Scale (VDS), Visual Analog Scale (VAS), and West Haven-Yale Multidisciplinary Pain Inventory (WHYMPI). Arthritis Care Res. 2003;49(S5):S96–S104.CrossRef Burckhardt CS, Jones KD. Adult measures of pain: The McGill Pain Questionnaire (MPQ), Rheumatoid Arthritis Pain Scale (RAPS), Short-Form McGill Pain Questionnaire (SF-MPQ), Verbal Descriptive Scale (VDS), Visual Analog Scale (VAS), and West Haven-Yale Multidisciplinary Pain Inventory (WHYMPI). Arthritis Care Res. 2003;49(S5):S96–S104.CrossRef
12.
go back to reference Gajewski BJ, Berry SM, Quintana M, Pasnoor M, Dimachkie M, Herbelin L, Barohn R. Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. Stat Med. 2015;34(7):1134–49.CrossRefPubMedPubMedCentral Gajewski BJ, Berry SM, Quintana M, Pasnoor M, Dimachkie M, Herbelin L, Barohn R. Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. Stat Med. 2015;34(7):1134–49.CrossRefPubMedPubMedCentral
13.
go back to reference Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRefPubMed Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRefPubMed
14.
go back to reference SAS software. Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA. SAS software. Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.
15.
go back to reference R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2012. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2012.
16.
go back to reference Collins SP, Lindsell CJ, Pang PS, Storrow AB, Peacock WF, Levy P, Rahbar MH, Del Junco D, Gheorghiade M, Berry DA. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am Heart J. 2012;164(2):138–45.CrossRefPubMedPubMedCentral Collins SP, Lindsell CJ, Pang PS, Storrow AB, Peacock WF, Levy P, Rahbar MH, Del Junco D, Gheorghiade M, Berry DA. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am Heart J. 2012;164(2):138–45.CrossRefPubMedPubMedCentral
18.
go back to reference Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? JAMA. 2012;307(22):2377–8.CrossRefPubMed Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? JAMA. 2012;307(22):2377–8.CrossRefPubMed
Metadata
Title
A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization
Authors
Alexandra R. Brown
Byron J. Gajewski
Lauren S. Aaronson
Dinesh Pal Mudaranthakam
Suzanne L. Hunt
Scott M. Berry
Melanie Quintana
Mamatha Pasnoor
Mazen M. Dimachkie
Omar Jawdat
Laura Herbelin
Richard J. Barohn
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Trials / Issue 1/2016
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-016-1544-5

Other articles of this Issue 1/2016

Trials 1/2016 Go to the issue